Literature DB >> 11917235

Transplacental genotoxicity of combined antiretroviral nucleoside analogue therapy in Erythrocebus patas monkeys.

Ofelia A Olivero1, Juan J Fernandez, Brendan B Antiochos, Jessica L Wagner, Marisa E St Claire, Miriam C Poirier.   

Abstract

Antiretroviral nucleoside analogue drugs are a major constituent of highly active antiretroviral therapy (HAART), the most advanced form of treatment for HIV-1 infection. Currently, HAART combinations that include zidovudine (ZDV) and lamivudine (3TC) are highly effective in preventing HIV-1 vertical transmission; most children are born with no evident adverse clinical effects. However, ZDV is a moderately strong transplacental carcinogen in mice, and potential long-term consequences of fetal exposure to most HAART combinations remain unknown. To model human transplacental ZDV and 3TC exposures, experiments were performed in Erythrocebus patas monkeys given human-equivalent drug exposure protocols. Pregnant monkeys were dosed with either no drug (n = 2), 40.0 mg ZDV/d (about 6 mg/kg body weight/d) for the last 50% (10 weeks) of gestation (n = 3), or with the same regimen of ZDV plus 24.0 mg 3TC/d (about 3.6 mg/kg body weight/d) for the last 20% (4 weeks) of gestation (n = 3). Multiple fetal organs were examined at term for DNA incorporation of ZDV and 3TC using two separate radioimmunoassays (RIAs). Values for ZDV-DNA incorporation were similar in fetuses exposed to ZDV alone and those exposed to ZDV plus 3TC. Values for 3TC-DNA in fetal organs were greater than or equal to values for ZDV-DNA, indicating that the total DNA damage sustained by fetuses exposed to both drugs was at least double that observed in fetuses exposed to ZDV alone. Telomere shortening, determined by Southern blot with a telomeric probe, was observed in most organs of the three animals exposed in utero to ZDV plus 3TC. No telomere shortening was evident in the unexposed fetuses, and occasional telomere shortening was found in fetuses exposed to ZDV alone. Overall, these studies demonstrate that monkey fetuses exposed in utero to the combination ZDV plus 3TC sustain a higher level of drug-DNA incorporation and show evidence of more telomere damage than monkey fetuses exposed to ZDV alone.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11917235     DOI: 10.1097/00126334-200204010-00001

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  14 in total

Review 1.  Should HIV discordant couples have access to assisted reproductive technologies?

Authors:  M Spriggs; T Charles
Journal:  J Med Ethics       Date:  2003-12       Impact factor: 2.903

2.  In utero exposure of female CD-1 mice to AZT and/or 3TC: II. Persistence of functional alterations in cardiac tissue.

Authors:  Salina M Torres; Rao L Divi; Dale M Walker; Consuelo L McCash; Meghan M Carter; Matthew J Campen; Tracey L Einem; Yvonne Chu; Steven K Seilkop; Huining Kang; Miriam C Poirier; Vernon E Walker
Journal:  Cardiovasc Toxicol       Date:  2010-06       Impact factor: 3.231

3.  Elevated frequencies of micronucleated erythrocytes in infants exposed to zidovudine in utero and postpartum to prevent mother-to-child transmission of HIV.

Authors:  Kristine L Witt; Coleen K Cunningham; Kristine B Patterson; Grace E Kissling; Stephen D Dertinger; Elizabeth Livingston; Jack B Bishop
Journal:  Environ Mol Mutagen       Date:  2007 Apr-May       Impact factor: 3.216

4.  A computational model of mitochondrial AZT metabolism.

Authors:  Patrick C Bradshaw; Jiaxin Li; David C Samuels
Journal:  Biochem J       Date:  2005-12-01       Impact factor: 3.857

5.  Human inter-individual variability in metabolism and genotoxic response to zidovudine.

Authors:  Ofelia A Olivero; Jessica M Ming; Shreyasi Das; Irma L Vazquez; Diana L Richardson; Ainsley Weston; Miriam C Poirier
Journal:  Toxicol Appl Pharmacol       Date:  2007-12-14       Impact factor: 4.219

Review 6.  Relevance of experimental models for investigation of genotoxicity induced by antiretroviral therapy during human pregnancy.

Authors:  Ofelia A Olivero
Journal:  Mutat Res       Date:  2008-01-12       Impact factor: 2.433

7.  Pyrimidine nucleoside depletion sensitizes to the mitochondrial hepatotoxicity of the reverse transcriptase inhibitor stavudine.

Authors:  Bernhard Setzer; Dirk Lebrecht; Ulrich A Walker
Journal:  Am J Pathol       Date:  2008-02-14       Impact factor: 4.307

8.  Interference of cell cycle progression by zidovudine and lamivudine in NIH 3T3 cells.

Authors:  Jia-Long Fang; Lynda J McGarrity; Frederick A Beland
Journal:  Mutagenesis       Date:  2008-10-20       Impact factor: 3.000

9.  Mutational analysis of the mitochondrial tRNA genes and flanking regions in umbilical cord tissue from uninfected infants receiving AZT-based therapies for prophylaxis of HIV-1.

Authors:  Salina M Torres; Dale M Walker; Consuelo L McCash; Meghan M Carter; Jessica Ming; Edmund M Cordova; Rachel M Pons; Dennis L Cook; Steven K Seilkop; William C Copeland; Vernon E Walker
Journal:  Environ Mol Mutagen       Date:  2009-01       Impact factor: 3.216

10.  Perinatal exposure of patas monkeys to antiretroviral nucleoside reverse-transcriptase inhibitors induces genotoxicity persistent for up to 3 years of age.

Authors:  Ofelia A Olivero; Lorangelly Rivera Torres; Sayeh Gorjifard; Dariya Momot; Eryney Marrogi; Rao L Divi; Yongmin Liu; Ruth A Woodward; Marsha J Sowers; Miriam C Poirier
Journal:  J Infect Dis       Date:  2013-04-04       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.